Imagine the outer shell of a cell is like a door that viruses use to sneak inside. This project created a pill that changes the 'stiffness' of that door, making it much harder for viruses to enter or move around. It also acts like a dimmer switch for the immune system, preventing the body from overreacting and causing dangerous inflammation.
Existing antivirals are often too specific to one virus strain, leaving populations vulnerable to emerging mutations and new outbreaks. There is a critical need for broad-spectrum treatments that stop multiple types of viruses from entering cells.
An oral small molecule (API batch) and a defined clinical trial design to test efficacy against COVID-19 and other viruses.
If you are a drug developer dealing with the constant threat of new viral outbreaks — this project developed an oral small molecule that limits virus internalization. It provides a broad-spectrum effect against multiple virus families, reducing the need to develop a new drug for every single strain.
If you are a health agency dealing with pandemic preparedness — this project developed a host-directed agent that targets cell mechanisms rather than the virus itself. This approach helps ward off outbreaks of coronaviruses, influenza, and flaviviruses using a single validated safety profile.
If you are a biotech firm dealing with cytokine storms or excessive immune reactions during infections — this project developed a molecule with immunomodulatory effects. It helps manage viral diseases by preventing the immune system from reacting excessively after infection.
Based on available project data, there is no information regarding the commercial price or cost per dose of the molecule.
The project successfully produced an API batch for the clinical trial, but the project was discontinued before full industrial scaling was detailed.
Based on available project data, specific patent numbers are not listed, but the coordinator Meletios Therapeutics developed the lead program presented at the EIC Accelerator.
Human safety has been validated, and the clinical trial design was defined before the project was discontinued.
The project was scheduled to run from 2023-01-01 to 2024-12-31, but work was stopped due to lack of funding.
The project was managed by a single SME, Meletios Therapeutics, based in France. With a 100% industry ratio and no university or research partners, the consortium was lean and focused entirely on commercial drug development.
Contact Meletios Therapeutics (FR) regarding the available API batch and clinical trial design.
Acquire the clinical trial design and API specifications for this broad-spectrum antiviral.
